Pressure BioSciences (OTCQB: PBIO) was recently granted
another patent to add to its intellectual property (“IP”) portfolio regarding
its development of an automated “hands-free” sample handling for the next
generation of the company’s high-pressure sample preparation platform systems.
A recent article discussing the company’s technology reads, “The global sample
preparation market is projected to reach $8.2 billion by 2024, according to a
report by TransparencyMarketResearch (http://ibn.fm/wCaOd). Pressure BioSciences’ product line is
led by its newly released, next-generation Barocycler 2320EXTREME instrument
system, which can be used to exquisitely control the sample preparation
process. Based on the company’s patented and enabling pressure cycling
technology (PCT) platform, over 300 Barocycler systems have been installed in
approximately 200 academic, government, pharmaceutical and biotech research
laboratories worldwide. These laboratories use the PCT instrument system for
multiple applications, including the preparation of samples for biomarker and
target discovery, soil & plant biology, anti-bioterror and forensics
studies. There are over 100 independent scientific publications highlighting
the advantages of the PCT system in such studies, many from worldwide key opinion
leaders.
To view the full article, visit http://ibn.fm/V2hNj
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e., pressure
cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of our pressure-based technologies in the following areas: (1) the use of
our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into
the biologics contract research services sector, and (2) the use of our recently-patented,
scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”)
platform to (i) create stable nanoemulsions of otherwise immiscible fluids
(e.g., oils and water) and to (ii) prepare higher quality, homogenized,
extended shelf-life or room temperature stable low-acid liquid foods that
cannot be effectively preserved using existing non-thermal technologies. For
more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
